View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Drug Delivery Market: Key Innovations in 2016

  • September 5, 2017

  • In her 2016 PODD “Year in Review,” Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche discussed several innovations that transformed the drug delivery market at PODD 2016. These innovations included:

    1. Miniature Magnetic Devices

    Researchers are exploring the use of miniature magnetic devices to treat diabetes, asthma and other diseases. Miniature magnetic devices are designed to change the firing patterns of peripheral nerves that go to muscles and organs, according to Lueckel. They also may provide safe, effective alternatives for patients who are struggling with pills and intravenous injections.

    GSK and Verily launched Galvani Bioelectronics, a company dedicated to the development of bioelectronics medicines, in August 2016. Meanwhile, as researchers drive miniature magnetic device innovations, investments in this field could increase in the years to come.

    2. Diabetes

    Approximately 3 million Americans – or about 9% of the U.S. population – are diabetic, the American Diabetes Association (ADA) reports. Fortunately, researchers are using innovation to improve diabetes diagnosis and treatment.

    For example, the J&J OneTouch Via device was introduced in June 2016 and offers mealtime insulin delivery for diabetics. Other notable diabetes innovations in 2016 included Repatha, a PCSK9 inhibitor that offers monthly single-dose delivery, and a Bluetooth-enabled insulin pen that tracks insulin dosing and other patient data.

    3. Connected Devices for Chronic Respiratory Diseases

    Roughly 500 million individuals suffer from chronic respiratory diseases, Lueckel indicated. Yet the digital dose inhaler market is projected to grow from $1 billion in 2016 to $4 billion by 2024, thanks in large part to ongoing innovation across the field.

    Connected devices simultaneously enhance compliance and dosage tracking and promote connectivity between chronic respiratory disease patients and healthcare providers. As such, the market for connected devices for chronic respiratory diseases represents “a huge growth opportunity” for patients and healthcare providers alike, Lueckel said.

    The drug delivery market is constantly evolving, and Lueckel will provide the latest insights into the sector’s past, present and future during her “Year in Review” presentation at this year’s PODD conference. To find out more about PODD, click here.